Evidence Snapshot

Carbonic anhydrase 2

CHEMBL205 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:08:51Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:08 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL205

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Carbonic anhydrase 2 as ChEMBL target CHEMBL205, mapped to UniProt P00918. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Carbonic anhydrase 2

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL205

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P00918

Carbonic anhydrase 2

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Carbonic anhydrase 2 matters

As of 2026-09-13

Carbonic anhydrase 2 is reviewed as Carbonic anhydrase 2 (UniProt P00918); Carbonic anhydrase 2 shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 76 approved drugs, 11454 compounds, and 1140 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Carbonic anhydrase 2

Carbonic anhydrase 2 Sequence length is 260 aa.

Review this target as Carbonic anhydrase 2, mapped to UniProt P00918. Sequence length is 260 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P00918 Protein

Disease context

glaucoma

Carbonic anhydrase 2 shows approved-linked disease relevance led by glaucoma. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ACETAZOLAMIDE, ACETAZOLAMIDE SODIUM, BRINZOLAMIDE.

Start review with glaucoma because it currently carries approved-linked support. Linked drugs include ACETAZOLAMIDE, ACETAZOLAMIDE SODIUM, BRINZOLAMIDE, DICHLORPHENAMIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 6 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 76 approved drugs, 11454 compounds, and 1140 assays for this target. The dominant activity type is KI. CHEMBL3608871 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL3608871 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

76 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Carbonic anhydrase 2 matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00918, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why glaucoma is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

11454

Total Compounds

1140

Total Assays

Approved Drugs

IC50: 2227.0, KI: 13626.0, KD: 945.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL3608871	11.0	Ki	—
No preferred name CHEMBL3608881	11.0	Ki	—
No preferred name CHEMBL3608883	11.0	Ki	—
No preferred name CHEMBL3608887	11.0	Ki	—
No preferred name CHEMBL3608888	11.0	Ki	—

Approved Drugs

Structure	Compound	First Approval
	TAVABOROLE CHEMBL443052	2014
	PAZOPANIB CHEMBL477772	2009
	LACOSAMIDE CHEMBL58323	2008
	NILOTINIB CHEMBL255863	2007
	HYDROQUINONE CHEMBL537	2002
	IMATINIB CHEMBL941	2001
	VALDECOXIB CHEMBL865	2001
	ZOLEDRONIC ACID CHEMBL4303669	2001
	ZONISAMIDE CHEMBL750	2000
	PIOGLITAZONE CHEMBL595	1999
	CELECOXIB CHEMBL118	1998
	BRINZOLAMIDE CHEMBL220491	1998
	TROGLITAZONE CHEMBL408	1997
	TOPIRAMATE CHEMBL220492	1996
	DORZOLAMIDE CHEMBL218490	1994
	FAMOTIDINE CHEMBL902	1986
	SULFANILAMIDE CHEMBL21	1985
	INDAPAMIDE CHEMBL406	1983
	ETHOXZOLAMIDE CHEMBL18	1982
	DOBUTAMINE CHEMBL926	1978
	MAFENIDE CHEMBL419	1969
	FUROSEMIDE CHEMBL35	1966
	TRICHLORMETHIAZIDE CHEMBL1054	1960
	CHLORTHALIDONE CHEMBL1055	1960
	HYDROCHLOROTHIAZIDE CHEMBL435	1959
	METHAZOLAMIDE CHEMBL19	1959
	DICHLORPHENAMIDE CHEMBL17	1958
	ACETAZOLAMIDE CHEMBL20	1953
	PROBENECID CHEMBL897	1951

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:08:51Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 5:08 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL205